UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of August 2023
 
Commission File Number: 001-36187

EVOGENE LTD.
  (Translation of Registrant’s Name into English)
 
13 Gad Feinstein Street, Park Rehovot, Rehovot
P.O.B 4173, Ness Ziona, 7414002, Israel
(Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F        Form 40-F
 


CONTENTS

On August 17, 2023, Evogene Ltd. (“Evogene”) announced its financial results for the second quarter ended June 30, 2023.  A Copy of the press release announcing those results is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) and is incorporated herein by reference.
 
The contents of Exhibit 99.1 to this Form 6-K, excluding the statements of Evogene’s President and CEO and Evogene’s CFO, contained therein, are incorporated by reference in the registration statements on Form F-3 (Securities and Exchange Commission (“SEC”) File No. 333-253300), and Form S-8 (SEC File Nos. 333-259215, 333-193788, 333-201443 and 333-203856) of Evogene, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.


 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 



Date: August 17, 2023
 
EVOGENE LTD.
(Registrant)

By: /s/ Yaron Eldad
Yaron Eldad
Chief Financial Officer

 

 
EXHIBIT INDEX
 
EXHIBIT NO.
DESCRIPTION

 

Exhibit 99.1

Evogene Reports Second Quarter 2023 Financial Results
 
Conference call and webcast: today, August 17, 2023, 9:00 am ET
 
Rehovot, Israel – August 17, 2023 – Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, today announced its financial results for the second quarter period ended June 30, 2023.
 
Ofer Haviv, Evogene’s President and Chief Executive Officer, stated: “The second quarter of 2023 marked a period of remarkable achievements for the Evogene group. It was a pivotal point in the transformation that Evogene has been undergoing since the creation of our three AI tech engines in 2019. Listing some of the main achievements in this period: announcing the receiving of purchase orders in the aggregate amount of $11.3 million for Casterra's elite castor seeds; execution of a licensing agreement between Lavie Bio and Corteva, which includes an upfront payment of $5 million, in addition to milestone and royalty payments; closing of a financial round for Biomica in the amount of $20 million; significant infrastructure and computational architecture improvements, including new applications, in our tech-engines resulting in new capabilities, and better automation, scalability, and speed; and last but not least, receiving the trust of high quality investors demonstrated by an investment in Evogene's equity in the gross amount of $8.5 million in our recent financing round, all happening in a relatively short timeframe. These are clear signals that the Evogene Group is on the right path to success.”
 
Mr. Haviv further stated: “In parallel, Evogene is increasing its efforts to establish direct collaborations with leading companies in new domains of activity, areas not currently covered by our subsidiaries, for product development leveraging our tech-engines. Although these discussions have only recently begun, the responses we have received to our unique offering have been positive, and we hope that some of these discussions will materialize into collaborative agreements in the near future.”
 


Evogene and Subsidiaries - Highlights
 
Evogene Ltd.
 

-
In July, Evogene successfully concluded a fundraising round, securing total gross proceeds of $8.5 million. The securities issued in this round were ordinary shares only and it did not include any warrant coverage.
 

-
In July, Evogene unveiled the latest enhancement to its ChemPass AI tech-engine: TargetSelector, a groundbreaking application designed to streamline target-protein discovery. TargetSelector uses predictive machine learning algorithms and genomic data to help researchers identify novel target proteins for innovative products. This addition to the ChemPass AI tech-engine, strongly position us to forge strategic partnerships with industry leaders, expediting product development and delivering novel solutions to pressing global needs, such as developing sustainable new pesticides and therapeutics.
 
Biomica Ltd. - develops microbiome-based therapeutics, leveraging Evogene’s MicroBoost AI tech-engine.
 

-
In April 2023, Biomica completed a $20 million financing round with a post-money valuation of $50 million, led by a $10 million investment from Shanghai Healthcare Capital.
 

-
BMC128, the company's leading candidate in its immune-oncology program, is currently in phase 1 clinical trial at Rambam Health Care Campus in Israel, aiming to evaluate its safety alongside BMS Opdivo® for Non-small-cell lung cancer, melanoma, and Renal cell carcinoma; the trial has enrolled 6 out of the planned 10-12 patients.
 

-
In August 2023, Biomica opened a second site in Israel at The Davidoff Cancer Center, to open the trial to additional potential patients for its BMC128 phase 1 clinical trial.
 

-
Biomica reported positive results from pre-clinical studies of BMC426 and BMC427 for Irritable bowel syndrome (IBS) treatment, in collaboration with Prof. Kara Gross Margolis at New York University. The studies showed that the live bacterial consortia were effective in reducing visceral pain, a major IBS symptom. Biomica will conduct additional pre-clinical studies and prepare for clinical trials.
 


Lavie Bio Ltd. - develops and commercializes microbiome-based ag-biological products, utilizing Evogene’s MicroBoost AI tech-engine.
 

-
Lavie Bio entered a licensing agreement with Corteva, conferring exclusive rights to Corteva for advancing and commercializing Lavie Bio's lead bio-fungicides, LAV311 and LAV312 - targeting fruit rots. This agreement follows two years of independent field validation trials conducted by both companies. Lavie Bio will receive an initial payment of $5 million, in two installments, and will also be eligible for additional future milestone payments and royalties from Corteva's sales of the products.
 

-
Thrivus™, Lavie Bio's bio-inoculant for spring wheat, has received regulatory approval from the Canadian Food Inspection Agency (CFIA). This approval triples the product's sales territory, expanding its global reach. Thrivus™ is already being used in the United States, where it has demonstrated its efficacy in increasing Hard Red Spring Wheat production by an average of 3-4 bushels per acre. This translates to a 4X return on investment for farmers.
 
AgPlenus Ltd. - aims to develop and commercialize next-generation crop protection products, utilizing Evogene’s ChemPass AI tech-engine.
 

-
Dr. Adrian Percy, an accomplished agricultural scientist with over 20 years of experience, joined AgPlenus' board of directors.
 

-
The integration of Evogene's TargetSelector application into AgPlenus's technology platform, powered by the ChemPass AI tech-engine, enhances the ability to identify new mode-of-action mechanisms, urgently needed to address the growing resistance of pests to existing commercial products. This advancement strengthens AgPlenus's potential for forging strategic partnerships with industry leaders.

Casterra Ltd. - provides an integrated end-to-end solution for large-scale castor bean cultivation, utilizing Evogene’s GeneRator AI tech-engine.
 

-
In June, Casterra signed a framework agreement with a prominent oil and gas company. The agreement secured initial purchase orders worth $9.1 million for the supply of castor seeds to be cultivated in specific African territories.
 

-
Later in June, Casterra received another purchase order, valued at $2.2 million, for additional territories in Africa.
 


Consolidated Financial Results Summary
 

-
As of June 30, 2023, Evogene had consolidated cash, cash equivalents and short-term bank deposits of approximately $33.9 million. Of this sum, Biomica accounted for $16.8 million, and Lavie Bio holds $7.1 million. Evogene, together with Casterra, Canonic, and AgPlenus, possessed an aggregate of $10.0 million in cash.
 
The injection of funds from the last round in July, total gross proceeds of $8.5 million, strengthens Evogene's financial position and provides the Company with the resources needed to execute its plans effectively and in a timely fashion. An example of such financial need is the significant increase in the required working capital of our wholly owned subsidiary, Casterra, to produce the castor seeds needed to fulfill the purchase orders received in the last months, totaling $11.3 million.

It is important to note that the $10 million reflected in the June 30th cash balance of Evogene together with Casterra, Canonic and AgPlenus, do not include funds raised by Evogene in July and any amount due under the purchase orders received by Casterra in the last few months, which are expected to be supplied during the second half of the year and at the beginning of next year. Further, note that the $7.1 million reflected in the cash balance of Lavie Bio, does not include the $5 million expected to be received as an upfront payment from the licensing agreement with Corteva that was announced in July.
 
During the second quarter, the consolidated cash usage was approximately $5.6 million, which included $2.8 million used by Lavie Bio and Biomica.


-
Revenues for the second quarter of 2023 were approximately $654 thousand compared to approximately $312 thousand in the same period the previous year. The revenue increase was primarily due to revenues recognized per the collaboration agreement of Evogene’s subsidiary AgPlenus with Corteva and from sales of Lavie Bio’s Thrivus product.





-
R&D expenses for the second quarter of 2023, which are reported net of non-refundable grants received, were approximately $5.4 million and remained stable as compared to approximately $5.4 million in the same period in the previous year.
 

-
Sales and marketing expenses were approximately $928 thousand for the second quarter of 2023 and slightly decreased as compared to approximately $962 thousand in the same period in the previous year. The main contributor to this decrease in expense was a reduction in personnel expenses at Canonic.
 

-
General and administrative expenses were approximately $1.8 million in the second quarter of 2023, compared to approximately $1.7 million in the same period in the previous year. The increase is mainly due to expenses related to share-based compensation.


-
Operating loss for the second quarter of 2023 was approximately $7.9 million, compared to an operating loss of approximately $8.0 million in the same period in the previous year.


-
Financing income, net of financing expenses, for the second quarter of 2023 was $0.1 million in comparison to financing expenses, net of financing income, of $1.7 million in the same period in the previous year. This difference was mainly due to the U.S. Dollar and Shekel exchange rate differences between periods, a decrease in marketable securities value in the second quarter of 2022 and an increase in interest income during the second quarter of 2023.
 

-
Net loss for the second quarter of 2023 was approximately $7.8 million, compared to a net loss of approximately $9.8 million in the same period in the previous year, mainly due to the financing expenses (income) differences as mentioned above.
 
For the full press release (includes financial tables), click here.
 
For an accessible file (includes financial tables), click here.
 
Evogene has published its updated investor presentation, which can be found on its investor relations’ website at:
 
https://www.evogene.com/investor-relations/presentations-and-webcasts/


 
Conference Call & Webcast Details:
 
Date: August 17, 2023. Time: 9:00 am ET; 4:00 pm IDT
 
Dial-in numbers:1-888-281-1167 toll-free from the United States, or +972-3-918-0609 internationally
 
Webcast & Presentation link available at:
 
https://www.evogene.com/investor-relations/presentations-and-webcasts/
 
The Company’s investor presentation can be viewed at the above link, which is in the investor relations section of the company website.
 
Replay Information: A replay of the conference call will be available approximately two hours following the completion of the call.
 
To access the replay, please dial 1-888-326-9310 toll-free from the United States or +972-3-925-5901 internationally. The replay will be accessible following the call for three days. An archive of the webcast will be available on the Company’s website.
 
About Evogene Ltd.
 
Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.
 
Evogene established three unique tech-engines – MicroBoost AI, ChemPass AI and GeneRator AI.  Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).
 
Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its five subsidiaries including:
 

-
Biomica Ltd. (www.biomicamed.com) – developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI;
 



-
Lavie Bio (www.lavie-bio.com) – developing and commercially advancing, microbiome based ag-biologicals powered by MicroBoost AI;
 

-
AgPlenus Ltd. (www.agplenus.com) – developing next generation ag-chemicals for effective and sustainable crop protection powered by ChemPass AI;
 

-
Canonic (www.canonicbio.com) – developing medical cannabis products based on decoding plant genetics for optimized therapeutic effect powered by GeneRator AI; and
 

-
Casterra Ag (www.casterra.co) – developing and marketing superior castor seed varieties producing high yield and high-grade oil content, on an industrial scale for the biofuel and other industries powered by GeneRator AI.
 
For more information, please visit: www.evogene.com.
 
Forward-Looking Statements
 
This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “could”, “expects”, “hopes” “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates”, “demonstrates” or words of similar meaning. For example, Evogene and its subsidiaries are using forward-looking statements in this press release when it discusses establishment of collaboration agreements with leading companies in new domains of activity, TargetSelector ability to identify novel target proteins for innovative products, the BMC426 and BMC427 for IBS treatment effectiveness in reducing visceral pain and related studies and trials, future milestone payments and royalties from Corteva's sales of Lavie Bio’s products, the resources needed to execute the company’s plans effectively and in a timely fashion, return on investment for farmers who use Thrivus, and the enhancement of AgPlenus’ ability to identify new pesticide mechanisms due to the use of Evogene's TargetSelector application. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance, or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, those risk factors contained in Evogene’s reports filed with the applicable securities authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
 
Evogene Investors’ Contact:
 
Rachel Pomerantz Gerber, Head of Investor Relations at Evogene
 
Email: rachel.pomerantz@evogene.com
 
Tel: +972-8-9311901
 

CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION


   
June 30,
   
December 31,
 
   
2023
   
2022
 
   
Unaudited
   
Audited
 
CURRENT ASSETS:
           
Cash and cash equivalents
 
$
20,233
   
$
28,980
 
Marketable securities
   
-
     
6,375
 
Short-term bank deposits
   
13,641
     
-
 
Trade receivables
   
178
     
348
 
Other receivables and prepaid expenses
   
1,419
     
1,482
 
Inventories
   
249
     
566
 
                 
     
35,720
     
37,751
 
LONG-TERM ASSETS:
               
Long-term deposits and other receivables
   
53
     
74
 
Deferred taxes
   
-
     
94
 
Right-of-use-assets
   
1,319
     
1,568
 
Property, plant and equipment, net
   
2,589
     
2,499
 
Intangible assets, net
   
13,659
     
14,140
 
                 
     
17,620
     
18,375
 
                 
   
$
53,340
   
$
56,126
 
CURRENT LIABILITIES:
               
Trade payables
 
$
1,078
   
$
1,036
 
Employees and payroll accruals
   
2,159
     
1,987
 
Lease liability
   
894
     
884
 
Liabilities in respect of government grants
   
541
     
79
 
Deferred revenues and other advances
   
392
     
22
 
Other payables
   
1,327
     
1,617
 
                 
     
6,391
     
5,625
 
LONG-TERM LIABILITIES:
               
Lease liability
   
585
     
932
 
Liabilities in respect of government grants
   
4,343
     
4,665
 
Other advances
   
578
     
-
 
Convertible SAFE
   
10,334
     
10,114
 
                 
     
15,840
     
15,711
 
SHAREHOLDERS' EQUITY:
               
Ordinary shares of NIS 0.02 par value:
Authorized − 150,000,000 ordinary shares; Issued and outstanding – 41,724,467  shares as of June 30, 2023 and 41,260,439 shares as of December 31, 2022
   
237
     
235
 
Share premium and other capital reserve
   
261,052
     
261,402
 
Accumulated deficit
   
(247,001
)
   
(233,707
)
                 
Equity attributable to equity holders of the Company
   
14,288
     
27,930
 
                 
Non-controlling interests
   
16,821
     
6,860
 
                 
   Total equity
   
31,109
     
34,790
 
                 
   
$
53,340
   
$
56,126
 




CONSOLIDATED INTERIM STATEMENTS OF PROFIT OR LOSS

U.S. dollars in thousands (except share and per share data)


   
Six months ended
June 30,
   
Three months ended
June 30,
   
Year ended December 31,
 
   
2023
   
2022
   
2023
   
2022
   
2022
 
   
Unaudited
   
Audited
 
                               
Revenues
 
$
1,295
   
$
549
   
$
654
   
$
312
   
$
1,675
 
Cost of revenues
   
783
     
425
     
461
     
262
     
909
 
                                         
Gross profit
   
512
     
124
     
193
     
50
     
766
 
                                         
Operating expenses (income):
                                       
                                         
Research and development, net
   
10,169
     
11,043
     
5,369
     
5,417
     
20,792
 
Sales and marketing
   
1,728
     
1,870
     
928
     
962
     
3,933
 
General and administrative
   
3,312
     
3,273
     
1,797
     
1,678
     
6,482
 
Other income
   
-
     
-
     
-
     
-
     
(3,500
)
                                         
Total operating expenses, net
   
15,209
     
16,186
     
8,094
     
8,057
     
27,707
 
                                         
Operating loss
   
(14,697
)
   
(16,062
)
   
(7,901
)
   
(8,007
)
   
(26,941
)
                                         
Financing income
   
699
     
485
     
391
     
444
     
516
 
Financing expenses
   
(785
)
   
(3,243
)
   
(247
)
   
(2,153
)
   
(3,329
)
                                         
Financing income (expenses), net
   
(86
)
   
(2,758
)
   
144
     
(1,709
)
   
(2,813
)
                                         
Loss before taxes on income
   
(14,783
)
   
(18,820
)
   
(7,757
)
   
(9,716
)
   
(29,754
)
Taxes on income (tax benefit)
   
(24
)
   
40
     
21
     
38
     
90
 
                                         
Loss
 
$
(14,759
)
 
$
(18,860
)
 
$
(7,778
)
 
$
(9,754
)
 
$
(29,844
)
                                         
Attributable to:
                                       
Equity holders of the Company
 
$
(13,294
)
 
$
(17,096
)
 
$
(7,023
)
 
$
(8,821
)
 
$
(26,638
)
Non-controlling interests
   
(1,465
)
   
(1,764
)
   
(755
)
   
(933
)
   
(3,206
)
                                         
   
$
(14,759
)
 
$
(18,860
)
 
$
(7,778
)
 
$
(9,754
)
 
$
(29,844
)
                                         
Basic and diluted loss per share, attributable to equity holders of the Company
 
$
(0.32
)
 
$
(0.42
)
 
$
(0.17
)
 
$
(0.21
)
 
$
(0.65
)
                                         
Weighted average number of shares used in computing basic and diluted loss per share
   
41,567,298
     
41,195,024
     
41,644,182
     
41,202,018
     
41,210,184
 




CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

   
Six months ended
June 30,
   
Three months ended
June 30,
   
Year ended December 31,
 
   
2023
   
2022
   
2023
   
2022
   
2022
 
   
Unaudited
   
Audited
 
   Cash flows from operating activities
                             
   Loss
 
$
(14,759
)
 
$
(18,860
)
 
$
(7,778
)
 
$
(9,754
)
 
$
(29,844
)
                                         
Adjustments to reconcile loss to net cash used in operating activities:
                                       
                                         
Adjustments to the profit or loss items:
                                       
                                         
Depreciation
   
807
     
717
     
406
     
371
     
1,513
 
Amortization of intangible assets
   
481
     
577
     
241
     
242
     
1,067
 
Share-based compensation
   
1,219
     
830
     
801
     
419
     
1,186
 
Revaluation of convertible SAFE
   
220
     
-
     
26
     
-
     
114
 
Net financing expenses
   
6
     
3,146
     
60
     
2,033
     
2,986
 
Loss from sale of property, plant and equipment
   
(26
)
   
-
     
-
     
-
     
-
 
Taxes on income (tax benefit)
   
(24
)
   
40
     
21
     
38
     
90
 
                                         
     
2,683
     
5,310
     
1,555
     
3,103
     
6,956
 
Changes in asset and liability items:
                                       
Decrease (increase) in trade receivables
   
170
     
170
     
72
     
55
     
(67
)
Decrease in other receivables
   
84
     
463
     
375
     
551
     
1,113
 
Decrease (increase) in inventories
   
317
     
(70
)
   
342
     
10
     
(474
)
Increase in deferred taxes
   
-
     
-
     
-
     
-
     
(94
)
Increase (decrease) in trade payables
   
26
     
(172
)
   
(95
)
   
(6
)
   
(469
)
Increase (decrease) in employees and payroll accruals
   
172
     
(278
)
   
117
     
(272
)
   
(675
)
Increase (decrease) in other payables
   
(162
)
   
(593
)
   
297
     
(147
)
   
48
 
Decrease in deferred revenues and other advances
   
(73
)
   
(159
)
   
(81
)
   
(99
)
   
(153
)
                                         
     
534
     
(639
)
   
1,027
     
92
     
(771
)
                                         
Cash received (paid) during the period for:
                                       
                                         
Interest received
   
283
     
80
     
145
     
31
     
186
 
Interest paid
   
(66
)
   
(227
)
   
(30
)
   
(103
)
   
(165
)
Taxes paid
   
(10
)
   
(29
)
   
(10
)
   
(27
)
   
(40
)
                                         
Net cash used in operating activities
 
$
(11,335
)
 
$
(14,365
)
 
$
(5,091
)
 
$
(6,658
)
 
$
(23,678
)




CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

   
Six months ended
June 30,
   
Three months ended
June 30,
   
Year ended December 31,
 
   
2023
   
2022
   
2023
   
2022
   
2022
 
   
Unaudited
   
Audited
 
Cash flows from investing activities:
                             
                               
Purchase of property, plant and equipment
   
(483
)
   
(747
)
   
(124
)
   
(305
)
 
$
(1,171
)
Proceeds from sale of marketable securities
   
6,924
     
12,149
     
6,287
     
2,725
     
12,356
 
Purchase of marketable securities
   
(503
)
   
(659
)
   
(503
)
   
(659
)
   
(911
)
Proceeds from sale of property, plant and equipment
   
26
     
-
     
-
     
-
     
-
 
Withdrawal from (investment in) bank deposits
   
(13,560
)
   
3,000
     
(13,560
)
   
-
     
3,000
 
                                         
Net cash provided by (used in) investing activities
 
$
(7,596
)
 
$
13,743
   
$
(7,900
)
 
$
1,761
   
$
13,274
 
                                         
Cash flows from financing activities:
                                       
                                         
Issuance of a subsidiary preferred shares to non-controlling interests
   
9,523
     
-
     
9,523
     
-
     
-
 
Proceeds from issuance of ordinary shares, net of issuance expenses
   
336
     
-
     
68
     
-
     
21
 
Proceeds from issuance of convertible SAFE
   
-
     
-
     
-
     
-
     
10,000
 
Proceeds from exercise of options
   
-
     
7
     
-
     
-
     
7
 
Repayment of lease liability
   
(413
)
   
(492
)
   
(207
)
   
(369
)
   
(803
)
Proceeds from government grants
   
1,089
     
30
     
1,063
     
-
     
149
 
Repayment of government grants
   
(35
)
   
(14
)
   
-
     
-
     
(31
)
                                         
Net cash provided by (used in) financing activities
   
10,500
     
(469
)
   
10,447
     
(369
)
   
9,343
 
                                         
Exchange rate differences - cash and cash equivalent balances
   
(316
)
   
(2,367
)
   
(223
)
   
(1,880
)
   
(2,284
)
                                         
Decrease in cash and cash equivalents
   
(8,747
)
   
(3,458
)
   
(2,767
)
   
(7,146
)
   
(3,345
)
                                         
Cash and cash equivalents, beginning of the period
   
28,980
     
32,325
     
23,000
     
36,013
     
32,325
 
                                         
Cash and cash equivalents, end of the period
 
$
20,233
   
$
28,867
   
$
20,233
   
$
28,867
   
$
28,980
 
                                         
Significant non-cash activities:
                                       
Acquisition of property, plant and equipment
 
$
90
   
$
66
   
$
21
   
$
66
   
$
74
 
Increase of right-of-use asset recognized with corresponding lease liability
 
$
135
   
$
30
   
$
64
   
$
-
   
$
90
 





Evogene (NASDAQ:EVGN)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Evogene Charts.
Evogene (NASDAQ:EVGN)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Evogene Charts.